Literature DB >> 20697958

Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry.

Felipe Carneiro da Silva1, Ligia Petrolini de Oliveira, Erika Monteiro Santos, Wilson Toshihiko Nakagawa, Samuel Aguiar Junior, Mev Dominguez Valentin, Benedito Mauro Rossi, Fábio de Oliveira Ferreira.   

Abstract

Lynch syndrome (LS) is caused by inherited germline mutations in mismatch repair (MMR) genes. It is one of the commonest forms of inherited predisposition to colorectal cancer (CRC), accounting for 2-5% of all CRC. LS is characterized by early age of onset, with a tendency for multiplicity and an increased risk for extra-colonic tumors at particular sites. In this study we have evaluated the frequency of extra-colonic tumors in 60 unrelated LS families fulfilling the Amsterdam criteria (ACI. ACII) from the Oncotree database of the Hereditary Colorectal Cancer Registry of the AC Camargo Hospital. All families' pedigree was extensively analyzed, varying from 2 to 6 generations with a total of 2,095 individuals evaluated. As expected, colorectal cancer was the most frequent tumor in the families (334 cases). We found 200 extracolonic tumors among all individuals with a higher ratio in women (123 cases) than men (77 cases). By far, breast cancer (32 cases) was the most frequent extracolonic manifestation in women followed by endometrial (20 cases) and uterine cervix cancer (20 cases). For man, prostate (16 cases) and stomach (12 cases) cancer were the most frequent extracolonic tumors. It is well know that establishing the diagnosis is challenging and requires knowledge and surveillance. Thus, recognition of individuals and families with hereditary predisposition to cancer according to clinical and molecular features, combined with intensive surveillance and management programs, can contribute substantially to improve results related to the diagnosis and characterization of LS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697958     DOI: 10.1007/s10689-010-9373-2

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  71 in total

1.  Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer?

Authors:  H F Vasen; H Morreau; J W Nortier
Journal:  Am J Hum Genet       Date:  2001-06       Impact factor: 11.025

Review 2.  An update of HNPCC (Lynch syndrome).

Authors:  H T Lynch; T Smyrk; J Lynch
Journal:  Cancer Genet Cytogenet       Date:  1997-01

Review 3.  Pathology of hereditary nonpolyposis colorectal cancer.

Authors:  J R Jass
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

4.  Patient accuracy of reporting on hereditary non-polyposis colorectal cancer-related malignancy in family members.

Authors:  N Katballe; S Juul; M Christensen; T F Ørntoft; F P Wikman; S Laurberg
Journal:  Br J Surg       Date:  2001-09       Impact factor: 6.939

5.  E-cadherin germline mutations in familial gastric cancer.

Authors:  P Guilford; J Hopkins; J Harraway; M McLeod; N McLeod; P Harawira; H Taite; R Scoular; A Miller; A E Reeve
Journal:  Nature       Date:  1998-03-26       Impact factor: 49.962

6.  Determinants of genital human papillomavirus detection in a US population.

Authors:  C L Peyton; P E Gravitt; W C Hunt; R S Hundley; M Zhao; R J Apple; C M Wheeler
Journal:  J Infect Dis       Date:  2001-05-09       Impact factor: 5.226

7.  Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer.

Authors:  Elise Renkonen; Yange Zhang; Hannes Lohi; Reijo Salovaara; Wael M Abdel-Rahman; Mef Nilbert; Kristiina Aittomaki; Heikki J Jarvinen; Jukka-Pekka Mecklin; Annika Lindblom; Paivi Peltomaki
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

Review 8.  The Lynch syndromes.

Authors:  H T Lynch; J F Lynch
Journal:  Curr Opin Oncol       Date:  1993-07       Impact factor: 3.645

9.  Identification of germ-line E-cadherin mutations in gastric cancer families of European origin.

Authors:  S A Gayther; K L Gorringe; S J Ramus; D Huntsman; F Roviello; N Grehan; J C Machado; E Pinto; R Seruca; K Halling; P MacLeod; S M Powell; C E Jackson; B A Ponder; C Caldas
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

10.  Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC).

Authors:  Johanne Geary; Peter Sasieni; Richard Houlston; Louise Izatt; Ros Eeles; Stewart J Payne; Samantha Fisher; Shirley V Hodgson
Journal:  Fam Cancer       Date:  2007-10-16       Impact factor: 2.375

View more
  18 in total

Review 1.  Colorectal cancer in the young, many questions, few answers.

Authors:  Kemal I Deen; Hiroshi Silva; Raeed Deen; Pramodh C Chandrasinghe
Journal:  World J Gastrointest Oncol       Date:  2016-06-15

2.  Lynch syndrome and cervical cancer.

Authors:  Yoland C Antill; James G Dowty; Aung Ko Win; Tina Thompson; Michael D Walsh; Margaret C Cummings; Steven Gallinger; Noralane M Lindor; Loïc Le Marchand; John L Hopper; Polly A Newcomb; Robert W Haile; James Church; Katherine M Tucker; Daniel D Buchanan; Joanne P Young; Ingrid M Winship; Mark A Jenkins
Journal:  Int J Cancer       Date:  2015-07-14       Impact factor: 7.396

3.  Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry.

Authors:  Mala Pande; Chongjuan Wei; Jinyun Chen; Christopher I Amos; Patrick M Lynch; Karen H Lu; Laura A Lucio; Stephanie G Boyd-Rogers; Sarah A Bannon; Maureen E Mork; Marsha L Frazier
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

4.  Elevated risk of prostate cancer among men with Lynch syndrome.

Authors:  Victoria M Raymond; Bhramar Mukherjee; Fei Wang; Shu-Chen Huang; Elena M Stoffel; Fay Kastrinos; Sapna Syngal; Kathleen A Cooney; Stephen B Gruber
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

5.  Extracolonic manifestations of lynch syndrome.

Authors:  Brian J Bansidhar
Journal:  Clin Colon Rectal Surg       Date:  2012-06

6.  Spectrum of mismatch repair gene mutations and clinical presentation of Hispanic individuals with Lynch syndrome.

Authors:  Annette Y Sunga; Charité Ricker; Carin R Espenschied; Danielle Castillo; Marilena Melas; Josef Herzog; Sarah Bannon; Marcia Cruz-Correa; Patrick Lynch; Ilana Solomon; Stephen B Gruber; Jeffrey N Weitzel
Journal:  Cancer Genet       Date:  2017-02-09

7.  Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases.

Authors:  Johanna E Lotsari; Annette Gylling; Wael M Abdel-Rahman; Taina T Nieminen; Kristiina Aittomäki; Marjukka Friman; Reino Pitkänen; Markku Aarnio; Heikki J Järvinen; Jukka-Pekka Mecklin; Teijo Kuopio; Päivi Peltomäki
Journal:  Breast Cancer Res       Date:  2012-06-12       Impact factor: 6.466

8.  Predictive models for mutations in mismatch repair genes: implication for genetic counseling in developing countries.

Authors:  Erika Maria Monteiro Santos; Mev Dominguez Valentin; Felipe Carneiro; Ligia Petrolini de Oliveira; Fabio de Oliveira Ferreira; Samuel Aguiar Junior; Wilson Toshihiko Nakagawa; Israel Gomy; Victor Evangelista de Faria Ferraz; Wilson Araujo da Silva Junior; Dirce Maria Carraro; Benedito Mauro Rossi
Journal:  BMC Cancer       Date:  2012-02-09       Impact factor: 4.430

9.  Investigating the Link between Lynch Syndrome and Breast Cancer.

Authors:  Megan Sheehan; Brandie Heald; Courtney Yanda; Erinn Downs Kelly; Stephen Grobmyer; Charis Eng; Matthew Kalady; Holly Pederson
Journal:  Eur J Breast Health       Date:  2020-04-01

10.  Mutation spectrum in South American Lynch syndrome families.

Authors:  Mev Dominguez-Valentin; Mef Nilbert; Patrik Wernhoff; Francisco López-Köstner; Carlos Vaccaro; Carlos Sarroca; Edenir Ines Palmero; Alejandro Giraldo; Patricia Ashton-Prolla; Karin Alvarez; Alejandra Ferro; Florencia Neffa; Junea Caris; Dirce M Carraro; Benedito M Rossi
Journal:  Hered Cancer Clin Pract       Date:  2013-12-18       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.